Glucocorticoid-induced hyperglycemia

Endocrine Practice

Volumn 15, Issue 5, 2009, Pages 469-474

  Clore, John N ^a   Thurby Hay, Linda ^a  

^a VIRGINIA COMMONWEALTH UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

2,4 THIAZOLIDINEDIONE DERIVATIVE; CYCLOSPORIN; DEXAMETHASONE; GLUCOSE; HYDROCORTISONE; INSULIN; ISOPHANE INSULIN; METFORMIN; MIFEPRISTONE; PREDNISOLONE; PREDNISONE; SULFONYLUREA; TACROLIMUS; GLUCOCORTICOID;

AGE DISTRIBUTION; APOPTOSIS; BODY FAT; BODY MASS; DIABETOGENESIS; DIET RESTRICTION; DISEASE ASSOCIATION; DOSE RESPONSE; DRUG DOSE REDUCTION; DRUG EFFECT; DRUG EFFICACY; DRUG POTENCY; DRUG SAFETY; DRUG TREATMENT FAILURE; GLUCONEOGENESIS; GLUCOSE BLOOD LEVEL; GLUCOSE INTOLERANCE; GLUCOSE TOLERANCE; HORMONE ACTION; HUMAN; HYPERGLYCEMIA; INCIDENCE; INSULIN RELEASE; INSULIN RESISTANCE; INSULIN SENSITIVITY; INSULIN SYNTHESIS; KIDNEY DISEASE; MEDICAL RECORD REVIEW; MEDLINE; NEUROLOGIC DISEASE; NON INSULIN DEPENDENT DIABETES MELLITUS; PANCREAS ISLET CELL; PLASMA HALF LIFE; PREDICTOR VARIABLE; PREGNANCY DIABETES MELLITUS; PREVALENCE; RECOMMENDED DRUG DOSE; REVIEW; RHEUMATOID ARTHRITIS; RISK ASSESSMENT; TREATMENT CONTRAINDICATION; TREATMENT DURATION; TREATMENT RESPONSE; WEIGHT CHANGE; CHEMICALLY INDUCED DISORDER; PATHOLOGY;

GLUCOCORTICOIDS; HUMANS; HYPERGLYCEMIA;

EID: 70449721289     PISSN: 1530891X     EISSN: None     Source Type: Journal    
DOI: 10.4158/EP08331.RAR     Document Type: Review

References (39)

1. Conn JW, Fajans SS. Influence of adrenal cortical steroids on carbohydrate metabolism in man. Metabolism. 1956;5:114-127.
2. Owen OE, Cahill GF Jr. Metabolic effects of exogenous glucocorticoids in fasted man. J Clin Invest. 1973;52:2596-2605.
3. Clement S, Braithwaite SS, Magee MF, et al (American Diabetes Association Diabetes in Hospitals Writing Committee). Management of diabetes and hyperglycemia in hospitals [published corrections appear in Diabetes Care. 2004;27:856 and Diabetes Care. 2004;27:1255]. Diabetes Care. 2004;27:553-591.
4. Gulliford MC, Charlton J, Latinovic R. Risk of diabetes associated with prescribed glucocorticoids in a large population. Diabetes Care. 2006;29:2728-2729.
5. Gurwitz JH, Bohn RL, Glynn RJ, Monane M, Mogun H, Avorn J. Glucocorticoids and the risk for initiation of hypoglycemic therapy. Arch Intern Med. 1994;154:97-101.
6. Conn HO, Poynard T. Corticosteroids and peptic ulcer: meta-analysis of adverse events during steroid therapy. J Intern Med. 1994;236:619-632.
7. Blackburn D, Hux J, Mamdani M. Quantification of the risk of corticosteroid-induced diabetes mellitus among the elderly. J Gen Intern Med. 2002;17:717-720.
8. Panthakalam S, Bhatnagar D, Klimiuk P. The prevalence and management of hyperglycaemia in patients with rheumatoid arthritis on corticosteroid therapy. Scott Med J. 2004;49:139-141.
9. Uzu T, Harada T, Sakaguchi M, et al. Glucocorticoid-induced diabetes mellitus: prevalence and risk factors in primary renal diseases. Nephron Clin Pract. 2007;105: c54-c57.
10. Iwamoto T, Kagawa Y, Naito Y, Kuzuhara S, Kojima M. Steroid-induced diabetes mellitus and related risk factors in patients with neurologic diseases. Pharmacotherapy. 2004;24:508-514.
11. Report of the Expert Committee on the Diagnosis and Classification of Diabetes Mellitus. Diabetes Care. 1997;20:1183-1197.
12. Clore JN, Estep H, Ross-Clunis H, Watlington CO. Adrenocorticotropin and cortisol-induced changes in urinary sodium and potassium excretion in man: effects of spironolactone and RU486. J Clin Endocrinol Metab. 1988;67:824-831.
13. Rizza RA, Mandarino LJ, Gerich JE. Cortisol-induced insulin resistance in man: impaired suppression of glucose production and stimulation of glucose utilization due to a postreceptor defect of insulin action. J Clin Endocrinol Metab. 1982;54:131-138.
14. Pagano G, Cavallo-Perin P, Cassader M, et al. An in vivo and in vitro study of the mechanism of prednisone-induced insulin resistance in healthy subjects. J Clin Invest. 1983;72:1814-1820.
15. Nicod N, Giusti V, Besse C, Tappy L. Metabolic adaptations to dexamethasone-induced insulin resistance in healthy volunteers. Obes Res. 2003;11:625-631.
16. Subramanian S, DeRosa MA, Bernal-Mizrachi C, et al. PPARalpha activation elevates blood pressure and does not correct glucocorticoid-induced insulin resistance in humans. Am J Physiol Endocrinol Metab. 2006;291:E1365-E1371.
17. Matsumoto K, Yamasaki H, Akazawa S, et al. High-dose but not low-dose dexamethasone impairs glucose tolerance by inducing compensatory failure of pancreatic beta-cells in normal men. J Clin Endocrinol Metab. 1996;81:2621-2626.
18. Wajngot A, Giacca A, Grill V, Vranic M, Efendic S. The diabetogenic effects of glucocorticoids are more pronounced in low- than in high-insulin responders. Proc Natl Acad Sci U S A. 1992;89:6035-6039.
19. Henriksen JE, Alford F, Ward GM, Beck-Nielsen H. Risk and mechanism of dexamethasone-induced deterioration of glucose tolerance in non-diabetic first-degree relatives of NIDDM patients. Diabetologia. 1997;40:1439-1448.
20. Vincenti F, Friman S, Scheuermann E, et al (DIRECT [Diabetes Incidence after Renal Transplantation: Neoral C Monitoring Versus Tacrolimus] Investigators). Results of an international, randomized trial comparing glucose metabolism disorders and outcome with cyclosporine versus tacrolimus [published corrections appear in Am J Transplant. 2008;8:908 and Am J Transplant. 2008;8:1]. Am J Transplant. 2007;7:1506-1514.
21. Redmon JB, Olson LK, Armstrong MB, Greene MJ, Robertson RP. Effects of tacrolimus (FK506) on human insulin gene expression, insulin mRNA levels, and insulin secretion in HIT-T15 cells. J Clin Invest. 1996;98:2786-2793.
22. Magee MH, Blum RA, Lates CD, Jusko WJ. Prednisolone pharmacokinetics and pharmacodynamics in relation to sex and race. J Clin Pharmacol. 2001;41:1180-1194.
23. Tóth GG, Kloosterman C, Uges DR, Jonkman MF. Pharmacokinetics of high-dose oral and intravenous dexamethasone. Ther Drug Monit. 1999;21:532-535.
24. Gustavson SM, Sandoval DA, Ertl AC, Bao S, Raj SR, Davis SN. Stimulation of both type I and type II corticosteroid receptors blunts counterregulatory responses to subsequent hypoglycemia in healthy man. Am J Physiol Endocrinol Metab. 2008;294:E506-E512.
25. Muggeo M, Verlato G, Bonora E, Zoppini G, Corbellini M, de Marco R. Long-term instability of fasting plasma glucose, a novel predictor of cardiovascular mortality in elderly patients with non-insulin-dependent diabetes mellitus: the Verona Diabetes Study. Circulation. 1997;96:1750-1754.
26. Ceriello A, Esposito K, Piconi L, et al. Oscillating glucose is more deleterious to endothelial function and oxidative stress than mean glucose in normal and type 2 diabetic patients. Diabetes. 2008;57:1349-1354.
27. Bibra H, Siegmund T, Ceriello A, Volozhyna M, Schumm-Draeger PM. Optimized postprandial glucose control is associated with improved cardiac/vascular function-comparison of three insulin regimens in well-controlled type 2 diabetes. Horm Metab Res. 2009;41:109-115.
28. Hoogwerf B, Danese RD. Drug selection and the management of corticosteroid-related diabetes mellitus. Rheum Dis Clin North Am. 1999;25:489-505.
29. Baldwin D Jr, Duffin KE. Rosiglitazone treatment of diabetes mellitus after solid organ transplantation. Transplantation. 2004;77:1009-1014.
30. Luther P, Baldwin D Jr. Pioglitazone in the management of diabetes mellitus after transplantation. Am J Transplant. 2004;4:2135-2138.
31. Villanueva G, Baldwin D. Rosiglitazone therapy of posttransplant diabetes mellitus. Transplantation. 2005;80:1402-1405.
32. Lago RM, Singh PP, Nesto RW. Congestive heart failure and cardiovascular death in patients with prediabetes and type 2 diabetes given thiazolidinediones: a meta-analysis of randomised clinical trials. Lancet. 2007;370:1129-1136.
33. Meier C, Kraenzlin ME, Bodmer M, Jick SS, Jick H, Meier CR. Use of thiazolidinediones and fracture risk. Arch Intern Med. 2008;168:820-825.
34. Trence DL. Management of patients on chronic glucocorticoid therapy: an endocrine perspective. Prim Care. 2003;30:593-605.
35. Kitzmiller JL, Block JM, Brown FM, et al. Managing preexisting diabetes for pregnancy: summary of evidence and consensus recommendations for care. Diabetes Care. 2008;31:1060-1079.
36. Holman RR, Thorne KI, Farmer AJ, et al (4-T Study Group). Addition of biphasic, prandial, or basal insulin to oral therapy in type 2 diabetes. N Engl J Med. 2007;357:1716-1730.
37. Campbell PJ, Gerich JE. Impact of obesity on insulin action in volunteers with normal glucose tolerance: demonstration of a threshold for the adverse effect of obesity. J Clin Endocrinol Metab. 1990;70:1114-1118.
38. Clore JN, Thurby-Hay L. Which basal insulin should be used in patients with type 2 diabetes mellitus? Curr Diab Rep. 2007;7:348-352.
39. Horvath K, Jeitler K, Berghold A, et al. Long-acting insulin analogues versus NPH insulin (human isophane insulin) for type 2 diabetes mellitus. Cochrane Database Syst Rev. 2007;CD005613.